List of Excipients in Branded Drug OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AvKARE	OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE	olmesartan medoxomil-hydrochlorothiazide	42291-924	CELLULOSE, MICROCRYSTALLINE
AvKARE	OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE	olmesartan medoxomil-hydrochlorothiazide	42291-924	FERRIC OXIDE RED
AvKARE	OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE	olmesartan medoxomil-hydrochlorothiazide	42291-924	FERRIC OXIDE YELLOW

Generic Drugs Containing OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Novadoz Pharmaceuticals LLC	olmesartan medoxomil-hydrochlorothiazide	72205-147	CELLULOSE, MICROCRYSTALLINE
Novadoz Pharmaceuticals LLC	olmesartan medoxomil-hydrochlorothiazide	72205-147	FERRIC OXIDE RED
Novadoz Pharmaceuticals LLC	olmesartan medoxomil-hydrochlorothiazide	72205-147	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW

Olmesartan Medoxomil-Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Olmesartan medoxomil-hydrochlorothiazide is an immediate-release, fixed-dose antihypertensive combination marketed in the United States as Benicar HCT. The product combines an angiotensin II receptor blocker with a thiazide diuretic in three strengths: 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg [1]. The primary commercial opportunity is a cost-efficient generic tablet with robust dissolution, stable moisture control, and reliable content uniformity at the low-dose hydrochlorothiazide level.

The strongest formulation strategy is a conventional, non-novel immediate-release tablet using a carefully controlled filler-disintegrant system, low-moisture processing, and a protective film coat. Differentiated opportunities exist in smaller tablets, improved swallowability, unit-dose packaging, lifecycle management, and potentially 505(b)(2) products with modified delivery or alternate dosage forms.

What excipients are used in olmesartan medoxomil-hydrochlorothiazide tablets?

The reference product uses standard oral solid dosage-form excipients associated with direct compression or wet-granulated immediate-release tablets. Public product information identifies excipient classes including microcrystalline cellulose, lactose monohydrate, hydroxypropyl cellulose, hypromellose, talc, titanium dioxide, colloidal silicon dioxide, and magnesium stearate [1,2].

Excipient class	Likely function	Strategic relevance
Microcrystalline cellulose	Diluent, compression aid, disintegration support	Supports tablet hardness and low-dose blend uniformity
Lactose monohydrate	Water-soluble diluent	Improves tablet mass and compactability
Hydroxypropyl cellulose	Binder	Supports granule strength and reduces friability
Crospovidone or croscarmellose sodium	Superdisintegrant	Accelerates tablet breakup and dissolution
Colloidal silicon dioxide	Glidant, moisture adsorbent	Improves flow and may reduce processing variability
Magnesium stearate	Lubricant	Controls ejection force but can slow dissolution if overused
Hypromellose	Film-forming polymer	Provides coating integrity and product identification
Talc	Anti-tacking and coating aid	Supports coating performance
Titanium dioxide	Opacifier and colorant	Provides light protection and visual differentiation

The exact quantitative composition of the reference product is not generally disclosed in the prescribing information. Generic manufacturers can use different excipients if the finished product satisfies pharmaceutical equivalence, bioequivalence, stability, dissolution, and quality requirements.

How do olmesartan medoxomil and hydrochlorothiazide affect excipient selection?

The combination creates two distinct formulation problems: low-dose uniformity for hydrochlorothiazide and dissolution control for olmesartan medoxomil.

Olmesartan medoxomil is a prodrug converted to olmesartan during absorption. Its formulation performance can be sensitive to particle size, wetting, granulation conditions, compression force, and storage moisture. Hydrochlorothiazide is present at 12.5 mg or 25 mg and requires consistent distribution throughout the blend, particularly in the 20 mg/12.5 mg strength.

A practical formulation must therefore achieve four targets:

1. Uniform distribution of hydrochlorothiazide.
2. Rapid and reproducible tablet disintegration.
3. Consistent release of both active ingredients.
4. Moisture and chemical stability through the labeled shelf life.

The formulation should be designed around the drug substances rather than around excipient cost alone. A lower-cost filler that increases segregation, slows dissolution, or raises stability risk can reduce the economic value of the product.

What is the best excipient platform for a generic tablet?

A robust baseline platform is a low-moisture direct-compression or dry-granulation process using microcrystalline cellulose, lactose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate.

Direct-compression platform

Direct compression offers the lowest process complexity and can reduce manufacturing cost. It is attractive where both active ingredients have suitable particle-size distribution and flow characteristics.

A representative platform would include:

• Microcrystalline cellulose as the principal compression aid.
• Lactose monohydrate as a secondary diluent.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate at the minimum effective concentration.
• A hypromellose-based film coating.

The principal risk is segregation. Differences in particle size, density, and surface properties between olmesartan medoxomil, hydrochlorothiazide, and the excipients can produce blend nonuniformity. Process controls should include particle-size specifications, ordered addition, controlled blending time, hopper management, and in-process content-uniformity sampling.

Dry-granulation platform

Roller compaction can improve blend uniformity, flow, and tablet weight control without introducing substantial water. It is useful when the active ingredients have poor flow or when wet granulation creates hydrolysis or stability concerns.

The main development risks are over-compaction, reduced tablet porosity, slower disintegration, and impaired dissolution. Milling conditions and ribbon density must be controlled. The formulation may require a higher superdisintegrant level or external disintegrant addition after granulation.

Wet-granulation platform

Wet granulation can improve content uniformity and compressibility, especially for a low-dose combination. It introduces greater manufacturing complexity and a higher moisture burden.

Aqueous processing should be evaluated cautiously because olmesartan medoxomil may be vulnerable to hydrolytic degradation under certain conditions. If wet granulation is required, a short, controlled process with rapid drying and tight residual-moisture limits is preferable. Organic or nonaqueous granulation may reduce water exposure but increases safety, environmental, and capital requirements.

Which excipient risks are most important for product development?

Moisture sensitivity

Water can affect active degradation, tablet hardness, dissolution, and coating performance. Excipients with variable moisture content should be qualified by supplier and lot. Lactose grade, microcrystalline cellulose moisture, and silica water content can influence both process behavior and stability.

The product should be evaluated under accelerated and long-term conditions with emphasis on:

• Olmesartan medoxomil degradation products.
• Hydrochlorothiazide assay and impurities.
• Dissolution changes over time.
• Tablet hardness and friability.
• Disintegration time.
• Water activity and residual moisture.

High-barrier blister packaging may be commercially preferable to standard high-density polyethylene bottles where stability data show a meaningful moisture effect.

Lubrication

Magnesium stearate is necessary for efficient tablet ejection but can create a hydrophobic surface when used at excessive levels or blended for too long. This can delay wetting and reduce dissolution.

Lubricant concentration and blending time should be treated as critical process parameters. Alternative lubricants such as sodium stearyl fumarate may support faster wetting in some formulations, but the change must be justified through comparative dissolution and stability data.

Low-dose hydrochlorothiazide distribution

The 12.5 mg strength presents the greatest content-uniformity challenge. A preblend or ordered dilution approach may be necessary. The manufacturer should avoid relying solely on final blend assay because sampling error can mask segregation.

A larger tablet mass can improve dose distribution but may reduce patient acceptability. The commercial objective is a compact tablet that maintains uniformity across the compression run.

Disintegration and dissolution

The product is an immediate-release tablet. A formulation that is excessively hard, highly lubricated, or under-disintegrated may fail comparative dissolution even if assay and content uniformity are acceptable.

Superdisintegrant selection should be based on:

• Disintegration speed.
• Dissolution in the required media.
• Sensitivity to compression force.
• Compatibility with the selected filler.
• Stability under storage humidity.

Crospovidone may provide rapid wicking and strong disintegration in some direct-compression systems. Croscarmellose sodium can provide swelling-driven disintegration. The preferred choice depends on tablet porosity and the selected manufacturing process.

What formulations are protected by patents or regulatory exclusivity?

The original branded product was approved by the FDA as Benicar HCT under NDA 021532. The U.S. product has historically been marketed in 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg strengths [1].

The principal commercial protection for this product has been associated with the olmesartan and combination-product patent estate, regulatory exclusivity, and litigation against generic applicants. The original composition and product patents are not the primary barrier to a new generic launch today. Any current launch assessment must rely on the FDA Orange Book, patent certifications, current litigation dockets, and applicable settlement terms rather than on the existence of historical patents alone [3].

A generic applicant generally faces the following regulatory framework:

• Abbreviated New Drug Application under section 505(j).
• Paragraph IV certification if a listed patent is asserted to be invalid, unenforceable, or not infringed.
• Paragraph III certification for a patent that has not expired.
• A requirement to demonstrate pharmaceutical equivalence and bioequivalence.
• Potential 180-day exclusivity if the applicant is a first valid Paragraph IV filer.

The relevant patent analysis should distinguish between patents covering the active ingredient, the combination, specific formulations, methods of treatment, and manufacturing processes. A formulation patent does not necessarily block every conventional tablet if the generic avoids the claimed excipient combination or process limitations.

When does olmesartan medoxomil-hydrochlorothiazide lose exclusivity?

The original small-molecule exclusivity period has expired, and generic versions of olmesartan medoxomil-hydrochlorothiazide have entered the U.S. market. The commercial question is therefore no longer whether the product can be copied in principle. It is whether a new entrant can obtain approval, secure supply, and compete on price without encountering an enforceable remaining patent or settlement restriction.

FDA Orange Book records should be checked by NDA, strength, and patent status before launch planning. Orange Book listings can change through patent expiration, delisting, court decisions, and FDA updates [3].

For business planning, exclusivity should be separated into four categories:

Protection category	Current strategic significance
FDA new-drug exclusivity	Historical protection; not the main current barrier
Active-ingredient patents	Primarily historical for the original product
Combination or formulation patents	Must be screened for any surviving claims
Regulatory and commercial barriers	More relevant than basic patent exclusion for many entrants

What FDA regulatory status applies to the combination?

Olmesartan medoxomil-hydrochlorothiazide is an FDA-approved prescription combination for hypertension. The reference product is an immediate-release oral tablet. The FDA label states that the combination is used when monotherapy is insufficient or as initial treatment in appropriate patients [1].

A standard generic application should target the reference-listed drug and establish:

• Same active ingredients.
• Same dosage form and route.
• Equivalent strength.
• Pharmaceutical equivalence.
• Bioequivalence.
• Comparable labeling, subject to permitted generic labeling changes.
• Adequate impurity, stability, and manufacturing controls.

A 505(b)(2) pathway may be relevant for a materially different formulation, such as an orally disintegrating tablet, a liquid, a modified-release system, or a product with a clinically meaningful delivery change. That pathway would create a different regulatory and patent strategy and may require additional clinical or pharmacokinetic evidence.

What commercial opportunities exist beyond a standard generic?

Low-cost conventional generic

The largest opportunity is a reliable multisource tablet with low manufacturing cost. The product has established clinical use and does not require a new efficacy program under an ANDA. Competition is likely to be price-driven, with supply reliability and wholesaler access determining market share.

Smaller tablet and improved swallowability

A smaller or lower-profile tablet can differentiate the product without changing its therapeutic concept. This requires efficient excipient selection, high tablet density, and careful coating control. The risk is increased compression force and slower disintegration.

Packaging-based differentiation

Moisture-barrier blister packaging, calendarized unit-dose packaging, and adherence-oriented configurations can support institutional, managed-care, and mail-order channels. Packaging differentiation is more likely to create a modest commercial premium than a durable patent moat.

Authorized or branded generic

A branded generic can compete where healthcare systems value continuity of supply, manufacturer qualification, or portfolio contracting. The product can be packaged alongside other antihypertensive products such as amlodipine, losartan, valsartan, or hydrochlorothiazide monotherapy.

Fixed-dose portfolio expansion

The combination can anchor a hypertension portfolio containing:

• Olmesartan medoxomil monotherapy.
• Olmesartan medoxomil-hydrochlorothiazide.
• Olmesartan medoxomil-amlodipine.
• Triple antihypertensive combinations where legally and clinically appropriate.

Portfolio breadth can reduce sales-force and distribution costs and improve contracting leverage.

Alternate dosage forms

An orally disintegrating tablet or sprinkle formulation could target patients with dysphagia. These products would require formulation development, taste and stability work, and a separate regulatory assessment. They may qualify for 505(b)(2) rather than ANDA treatment if they differ materially from the reference product.

How strong is the patent estate for this product?

The patent estate is weaker as a barrier to conventional generic entry than it was during the branded product’s launch period. A generic developer’s risk is more likely to arise from residual Orange Book listings, formulation-specific claims, litigation timing, or commercial execution than from the basic ability to formulate the two active ingredients.

Patent strength should be assessed across five dimensions:

1. Claim scope: whether claims cover the active combination broadly or only narrow excipient or process features.
2. Remaining term: whether any listed patent remains enforceable at the planned launch date.
3. Validity: whether prior art raises obviousness, anticipation, enablement, or written-description concerns.
4. Design-around feasibility: whether the generic can replace a claimed excipient, process step, or coating system.
5. Litigation posture: whether the reference sponsor has sued after a Paragraph IV notice and whether a 30-month stay applies.

Manufacturing-process patents may have limited practical value if the generic can use a different granulation, compression, coating, or impurity-control process. Formulation claims can be more relevant when they are drafted broadly around dissolution, particle size, or a defined excipient ratio.

What generic launch risks exist?

The principal launch scenarios are:

Launch scenario	Business implication
Fully cleared ANDA with no blocking patent	Immediate competitive launch subject to approval and supply readiness
Paragraph IV challenge with no litigation stay	Potential early launch, with litigation risk
Paragraph IV challenge followed by litigation	Approval may be delayed by a 30-month stay or court outcome
Paragraph III certification	Launch deferred until the listed patent expires
Settlement-limited launch	Entry date depends on negotiated terms
Approval without commercial supply	Lost opportunity despite regulatory clearance

The most material technical risks are failure of bioequivalence, dissolution mismatch, blend uniformity failure, and stability degradation. The most material commercial risks are price erosion, limited wholesaler allocation, API supply interruptions, and weak contracting access.

Which companies are challenging or competing with the reference product?

The combination has been subject to generic competition from multiple manufacturers over time. The active competitive field typically includes large generic companies, specialty generics manufacturers, contract manufacturing organizations, and regional suppliers.

Competitive analysis should compare:

• Number of approved ANDAs by strength.
• Current active suppliers.
• FDA shortage or supply notices.
• API source concentration.
• Product discontinuation history.
• Wholesale acquisition cost and reimbursement.
• Authorized-generic relationships.
• Manufacturing location and inspection record.

Because the product is an established generic combination, competitive advantage is more likely to come from dependable supply, low cost of goods, and portfolio contracting than from a novel excipient claim.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are moderate. The active ingredients are established small molecules, and the dosage form is a conventional tablet. The key technical barriers are process control and stability rather than novel delivery technology.

A commercially efficient development program should:

• Qualify multiple API sources where possible.
• Control olmesartan medoxomil particle size and polymorphic form.
• Use low-moisture excipients.
• Establish a robust hydrochlorothiazide preblend.
• Set dissolution specifications that discriminate against process drift.
• Evaluate high-barrier packaging early.
• Screen alternative lubricants and disintegrants for design-around value.
• Preserve process flexibility across tablet strengths.

The formulation should avoid unnecessary dependence on a single proprietary excipient grade unless that grade materially improves performance. Commodity excipients provide a stronger long-term supply position and reduce licensing exposure.

Key Takeaways

• Olmesartan medoxomil-hydrochlorothiazide is an established immediate-release combination marketed in three principal strengths.
• The best generic platform is a conventional tablet using microcrystalline cellulose, lactose or another suitable diluent, a superdisintegrant, silica, magnesium stearate, and a protective film coat.
• Moisture control, hydrochlorothiazide content uniformity, and dissolution are the main formulation risks.
• A direct-compression process offers the lowest cost, while dry granulation provides a useful fallback when flow or uniformity is inadequate.
• The original exclusivity period has expired, making manufacturing economics and supply reliability more important than basic patent ownership.
• Any launch decision still requires a current Orange Book and litigation review for surviving patents, Paragraph IV activity, and settlement restrictions.
• Commercial differentiation is most credible through smaller tablets, packaging, portfolio contracting, alternate dosage forms, and reliable supply.
• Manufacturing-process and narrow formulation patents may be avoidable through excipient substitution and process redesign.

FAQs

Is olmesartan medoxomil-hydrochlorothiazide suitable for an ANDA?

Yes. A conventional generic tablet can generally be pursued through the ANDA pathway if it matches the reference product in active ingredients, dosage form, route, strength, pharmaceutical equivalence, and bioequivalence.

Which strength presents the greatest formulation challenge?

The 20 mg/12.5 mg strength typically presents the greatest content-uniformity challenge because hydrochlorothiazide is present at a relatively low dose. Blend segregation and sampling strategy require particular attention.

Can a generic manufacturer replace the reference product’s excipients?

Yes. FDA-approved generics do not have to use the identical inactive ingredients unless a specific excipient is necessary for safety, performance, or dosage-form functionality. The substitute formulation must meet applicable quality and bioequivalence requirements.

Is an orally disintegrating version likely to use an ANDA?

Not necessarily. A materially different orally disintegrating formulation may require a 505(b)(2) application, depending on FDA determinations concerning dosage form, labeling, bioequivalence, and reliance on the reference product.

Does hydrochlorothiazide create a separate patent barrier?

Hydrochlorothiazide is an old, widely used active ingredient and generally is not the main patent barrier. The relevant risks are more likely to involve the combination, formulation, manufacturing process, or remaining Orange Book-listed patents.

References

1. U.S. Food and Drug Administration. (2023). Benicar HCT: Prescribing information. Daiichi Sankyo, Inc.

2. National Library of Medicine. (2024). DailyMed: Olmesartan medoxomil and hydrochlorothiazide tablet labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly soluble, highly permeable, and highly bioavailable drug products. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for industry.